In the 15 years since the Human Genome Project was completed, the genomic revolution has spurred immeasurable excitement and support surrounding the promise of personalized medicine, setting high expectations for a new era of health care and rapidly transforming the field into a multi-billion dollar industry. While realizing that promise has been neither quick nor easy, recent scientific and technological progress points to a possible tipping point for mainstream clinical adoption as well as tremendous commercial potential for innovators, entrepreneurs, and investors.
For a deep-dive into this potential and how to capitalize on it, join Foley, the Personalized Medicine Coalition, and key industry stakeholders on December 6 in South San Francisco for the annual Business of Personalized Medicine Summit. Now in its fifth year, this unique one-day thought leadership forum explores sustainable business model solutions for entities that are already engaged in the personalized medicine marketplace as well as those seeking to enter the competitive space.
Through a series of thought-provoking discussions, the program will examine the latest financial, regulatory, policy, R&D, and technology-related complexities, trends, and opportunities impacting the business of personalized medicine, and introduce strategies for successfully navigating this challenging and ever-evolving market.
To register for this can’t-miss day of industry networking and thought leadership, please click here. Registration is complimentary for life sciences and healthcare executives, entrepreneurs, investors, and academics. For more information, visit www.personalizedmedicinesummit.com or contact Allison Jones at firstname.lastname@example.org.
Helmy Eltoukhy, PhD, Co-Founder & Chief Executive Officer, Guardant Health
Harry Glorikian, MBA, Senior Executive, Board Director, Consultant & Investor, Author of “MoneyBall Medicine”
Edward Abrahams, PhD, President, Personalized Medicine Coalition
Blanca Baez, MBA, Senior Vice President and Global Head, Pharma & Biotech, Molecular Health
Nathan A. Beaver, Partner, Foley & Lardner LLP
Thomas Brown, MD, MBA, Executive Director, Swedish Cancer Institute & Co-Chairman, Providence Health & Services Personalized Medicine Program
Anita J. Chawla, PhD, Managing Principal, Analysis Group
Curt P. Creely, Partner, Foley & Lardner LLP
Jennifer Dyer, Executive Director, USC Stevens Center for Innovation
James Ford, MD, Director, Clinical Cancer Genetics Program, Stanford Health Care & Associate Professor of Medicine and Genetics, Stanford University School of Medicine
Matt Gardner, Founder and Chief Executive Officer, California Technology Council
David Hardison, PhD, Vice President, Health Sciences, ConvergeHEALTH by Deloitte
Alexis Ji, PhD, MBA, Partner, Illumina Ventures
Mickey Kertesz, PhD, Chief Executive Officer, Karius Dx
Caitlyn Krebs, Chief Business Officer, Bluestar Genomics, Inc.
Patricia Lawman, PhD, Chief Executive Officer, Morphogenesis, Inc.
J. Blake Long, MD, MBA, Investor Member and Life Sciences Due Diligence Lead, Ariel Southeast Angel Partners & President, Long Health Care Consulting
Trevor Martin, PhD, Co-Founder & Chief Executive Officer, Mammoth Biosciences
Mark McCoy, MBA, Vice President, Reimbursement, Guardant Health
Lincoln Nadauld, MD, PhD, Executive Director, Precision Medicine and Precision Genomics, Intermountain Healthcare
Jonathan Norris, Managing Director of Sales Origination, Silicon Valley Bank
Neena Patil, Senior Vice President, General Counsel and Corporate Secretary, Abeona Therapeutics
Girish Putcha, MD, PhD, Chief Medical Officer and Clinical Laboratory Director, Freenome
Bruce Quinn, MD, PhD, Principal, Bruce Quinn Associates LLC
James S. Scibetta, Chief Executive Officer, Maverick Therapeutics
Dan Snyder, MBA, President and Chief Executive Officer, MolecularMD
Ashley Van Zeeland, PhD, MBA, Vice President, Product Development, Business Operations and Systems Integration, Illumina
Jo Varshney, DVM, PhD, Founder and Chief Executive Officer, VeriSIM Life
Judith A. Waltz, Partner, Foley & Lardner LLP